| DBL — Diffuse B-Cell Lymphoma | |
|---|---|
| Symbol | DBL |
| Full Name | DBL Proto-Oncogene, Rho GEF (MCF2) |
| Chromosome | Xq27.1 |
| NCBI Gene | 9075 |
| Ensembl | ENSG00000123146 |
| UniProt | P12931 |
| Diseases | B-Cell Lymphoma, Prostate Cancer, X-Linked Mental Retardation |
| Expression | Brain, Spleen, Testis, Lymphoid tissues |
Dbl Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DBL (also known as MCF2) is a proto-oncogene that encodes a Rho guanine nucleotide exchange factor (RhoGEF). DBL was originally identified as an oncogene from a diffuse B-cell lymphoma. The protein functions as a specific activator of Rho GTPases, particularly RhoA, Rac1, and Cdc42, which are critical regulators of the actin cytoskeleton.
DBL is a prototypic RhoGEF that catalyzes the exchange of GDP for GTP on Rho GTPases:
In neurons, DBL and related RhoGEFs regulate:
DBL participates in several signaling cascades:
DBL was originally discovered as an oncogene in diffuse B-cell lymphoma. Dysregulation contributes to:
Given its role in neuronal development:
The Rho GTPase pathways are relevant to:
The study of Dbl Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.